SCHEMBL684045

SCHEMBL684045

Cc1cccc(N2CCN(Cn3cnc4c3c(=O)n(C)c(=O)n4C)CC2C)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
HTR7 P34969 1/20 0.48
HTR6 P50406 1/20 0.48
MAPK1 P28482 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
ADORA2B P29275 3/20 0.44
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44
UBE2N P61088 1/20 0.44
TRPA1 O75762 1/20 0.44
RXFP1 Q9HBX9 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683664 0.91 MAPK1 (0.56) MAPTHTR7HTR6MAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL11153642 0.89 HTR7 (0.61) MAPTHTR7HTR6MAPK1SMN1; SMN2
SCHEMBL682822 0.89 RXFP1 (0.57) MAPTHTR7HTR6MAPK1SMN1; SMN2
SCHEMBL683656 0.84 HTR7 (0.61) MAPTHTR7HTR6MAPK1SMN1; SMN2
SCHEMBL682832 0.84 MAPT (0.49) MAPTMAPK1ADORA2BGLAMEN1
SCHEMBL11153511 0.79 HTR7 (0.71) MAPTHTR7HTR6MAPK1SMN1; SMN2
SCHEMBL11150100 0.76 HTR7 (0.78) HTR7HTR6MAPK1L3MBTL1ADORA2B
SCHEMBL683669 0.75 MAPK1 (0.45) MAPTMAPK1SMN1; SMN2L3MBTL1ADORA2B
SCHEMBL683655 0.75 HTR7 (0.77) MAPTHTR7HTR6MAPK1SMN1; SMN2
SCHEMBL683995 0.75 MAPK1 (0.72) MAPTHTR7HTR6MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF MAPT 1368/4885HTR7 1398/4885HTR6 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.